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RESEARCH LETTERSMarked Elevation of
Plasma Levels of
Oxidative Stress-
Responsive Apoptosis-
Inducing Protein in
Dialysis PatientsTo the Editor: Cardiovascular injury is known to
play a critical role in the morbidity and mortality
associated with chronic kidney disease (CKD), espe-
cially in end-stage renal disease (ESRD), such as in
dialysis patients. Although oxidative stress, rather
than traditional cardiovascular risk factors such as
diabetes, hypertension, hypercholesterolemia, and
smoking, has been implicated in the mechanisms of
cardiotoxicity in CKD,1 the precise mechanism remains
unclear. Recently, we identiﬁed an apoptosis-inducing
humoral factor, in a conditioned medium from cardiac
myocytes subjected to hypoxia/reoxygenation, to be a
tyrosine-sulfated and more hypusinated secreted form
of eukaryotic translation initiation factor 5A (eIF5A).2
We found that eIF5A undergoes 69th tyrosine-
sulfation in the trans-Golgi and is rapidly secreted
from cardiac myocytes in response to hypoxia/reox-
ygenation, and then induces apoptosis by acting as a
pro-apoptotic ligand. The apoptosis of cardiac myo-
cytes induced by hypoxia/reoxygenation was sup-
pressed by anti-eIF5A neutralizing monoclonal
antibodies in vitro. Myocardial ischemia/reperfusion
(but not ischemia only) rapidly and markedly
increased plasma levels of eIF5A, which returned
to the control levels within 60 minutes. Treatment
with anti-eIF5A neutralizing monoclonal antibodies
signiﬁcantly reduced myocardial injury. These
results demonstrated that a novel, posttranslationally
modiﬁed, secreted form of eIF5A is a speciﬁc
biomarker and a critical therapeutic target for oxida-
tive stressinduced cell injury. We named this
novel tyrosine-sulfated secreted form of eIF5A,
oxidative stress-responsive apoptosis-inducing pro-
tein (ORAIP).2 We conﬁrmed that ORAIP (molecular
weight 17 kD, isoelectric point 5.4) is speciﬁcally
secreted in response to the oxidative stresses including
ischemia/reperfusion, hypoxia/reoxygenation, ultraviolet-
irradiation, ionizing radiation, cold/warm-stress (heat
shock), and blood acidiﬁcation,2,3 then acts as a pro-
apoptotic ligand to induce apoptosis of target cells
such as cardiac myocytes. To investigate the roles ofKidney International Reports (2016) 1, 321–326ORAIP in the oxidative stressinduced cytotoxicity
in ESRD, we analyzed the plasma levels of ORAIP in
ESRD patients just before and after dialysis. This study
was carried out in accordance with the Declaration of
Helsinki (2000) of the World Medical Association, and
was approved by the Institutional Ethical Committees.
All patients and control subjects gave written
informed consent after full explanation of the purpose,
nature, and risks of all procedures used.
A total of 62 ESRD (dialysis) patients (37 male and
25 female [male/female ¼ 1.48]), with a mean ( SE)
age of 72.05  1.37 years, and 40 age- and sex-
matched control subjects without apparent CKD
(24 male and 16 female [male/female ¼ 1.50]), aged
70.55  1.40 years, were studied. The characteristics
of the ESRD (dialysis) and control groups are sum-
marized in Table 1. The causative diseases of ESRD
(dialysis) patients were (diabetic nephropathy, 24
cases; chronic glomerulo nephritis, 19; nephro-
sclerosis, 10; polycystic kidney diease, 2; IgA
nephropathy, 2; focal glomerulosclerosis, 2; mem-
branoproliferative glomerulonephritis, 1; chronic py-
elonephritis, 1; and postoperative renal cell cancer, 1).
Plasma ORAIP levels were analyzed by the sandwich
enzyme-linked immunosorbent assay using block-
ingless type plates (Sumitomo Bakelite Co., Ltd,
Tokyo, Japan) as described previously.2
In dialysis patients, plasma blood urea nitrogen,
creatinine, and uric acid levels (mean  SE) were
markedly decreased by dialysis (from 62.91  2.15
mg/dl to 19.39  0.80 mg/dl; from 9.80  0.37 mg/dl to
3.65  0.16 mg/dl; and from 6.92  0.13 to 2.02  0.07
mg/dl, respectively. In contrast, plasma ORAIP levels
before dialysis (mean  SE 93.6  5.1 ng/ml), which
were markedly elevated as compared with those of
control subjects (6.6  1.5 ng/ml), signiﬁcantly
increased after dialysis (98.5  5.7 ng/ml, P ¼ 0.0122,
paired t test) (Figure 1). This suggests that ORAIP may
be somewhat concentrated but not eliminated by
dialysis. To investigate the effects of marked elevation
of plasma ORAIP levels on cardiovascular injury, we
analyzed plasma levels of cardiac troponin T and brain
natriuretic peptide (BNP). In all dialysis patients,
plasma cardiac troponin T levels (mean  SE, 67.9 
6.6 pg/ml) were elevated; however, there was no sig-
niﬁcant correlation (r ¼ 0.0945, P ¼ 0.4651) between
plasma levels of ORAIP and cardiac troponin T
(Figure 2A). In most dialysis patients, plasma BNP
levels (mean  SE, 164.7  22.3 pg/ml) were markedly
elevated; however, there was no signiﬁcant correlation
(r ¼ 0.1353, P ¼ 0.2944) between plasma levels of
ORAIP and BNP (Figure 2B). No signiﬁcant correlations321
Table 1. Characteristics of the CKD patient group and control group
ESRD patients Controls
n 62 40
Sex (male/female) 37/25 (1.48a) 24/16 (1.50a)
Age (yr) 72.05  1.37 70.55  1.40
Smoking (n) 24 (38.7%) 12 (30.0%)
Hypertension (n) 54 (87.1%) 27 (67.5%)
Diabetes mellitus (n) 26 (41.9%) 27 (67.5%)
Dyslipidemia (n) 20 (32.3%) 20 (50.0%)
Dialysis vintage (yr) 7.40  0.95
Dialysis time (h) 4.03  0.03
Removal amount (L) 2.32  0.09
Ultraﬁltration rates (L/h) 0.58  0.02
Kt/V 1.40  0.03
CKD, chronic kidney disease; ESRD, end-stage renal disease.
Values expressed as (mean  SE) or as numbers (%) unless otherwise speciﬁed.
aMale-to-female ratio.
RESEARCH LETTERSwere found between plasma levels of ORAIP and those
of blood urea nitrogen (r ¼ 0.190, P ¼ 0.139),
creatinine (r ¼ 0.111, P ¼ 0.390), and uric acid
(r ¼ 0.078, P ¼ 0.548).
In the ﬁrst report investigating the plasma levels of
ORAIP in human samples, we have demonstrated that
plasma levels of ORAIP were markedly elevated in
dialysis patients and that ORAIP could not be elimi-
nated by dialysis. From our previous in vitro and
in vivo data in an animal model,2 it is stronglyFigure 1. Plasma levels of oxidative stress-responsive apoptosis-
inducing protein (ORAIP) in control subjects and chronic kidney
disease (CKD) patients before and after dialysis. Plasma levels of
ORAIP (mean  SD) in control subjects, and individual values and
(mean  SD) of plasma levels of ORAIP in CKD patients before and
after dialysis, are shown. *P ¼ 0.0122 compared with before dialysis,
as determined by a paired t test.
322suggested that chronically elevated plasma levels of
ORAIP contribute, at least in part, to myocardial
injury in these patients. Other cardiotoxic factors
such as oxidized low-density lipoprotein, reactive
oxygen species, parathyroid hormone, anemia, and
others are known to be involved in the myocardial
injury in CKD and ESRD, and we found that there
were no signiﬁcant correlations between the plasma
levels of ORAIP and serum levels of parathyroid
hormone as well as anemia, suggesting that ORAIP
contributes to myocardial injury independently of
other factors. Because numerous factors may
contribute to myocardial injury, the absence of a
signiﬁcant positive correlation between plasma levels
of ORAIP and cardiac troponin T does not exclude the
possibility that ORAIP may contribute to the
myocardial injury involved in dialysis patients,
which may in turn, at least in part, exacerbate heart
failure associated with these patients, resulting in the
elevation of plasma BNP levels. Because we also found
that ORAIP can induce apoptotic signaling in skeletal
muscle cells,2 it is suggested that elevated plasma
levels of ORAIP affect skeletal muscles as well as
cardiac muscle, and may contribute, at least in part, to
sarcopenia in ESRD patients.4 Oxidative stress has
been implicated in the pathogenesis in dialysis pa-
tients,5–7 and it was reported that inﬂammatory status
and duration of dialysis treatment are the most
important factors relating to the oxidative stress
involved.8 Dialysis therapies are known to enhance
serum levels of cytokines as well as other uremic
toxins, although the mechanisms have been contro-
versial.9 Nguyen et al.10 reported that hemodialysis
membrane induced activation of phagocytes that
produce reactive oxygen species. Thus, oxidative
stress is known to be induced by the dialysis pro-
cedure itself, and this may contribute in part to the
increase in plasma ORAIP levels after dialysis.
Xanthine oxidase is an enzyme involved in purine
metabolism and also produces reactive oxygen spe-
cies. Recently, it was reported that xanthine oxidase
activity, but not uric acid levels, was an independent
predictor of cardiovascular events in CKD and
hemodialysis patients.11 This suggests that oxidative
stress induced by xanthine oxidase causes cardio-
vascular injury and supports that elevated levels of
plasma ORAIP induced by oxidative stress mediate
cardiovascular injury in ESRD patients. Because
plasma ORAIP levels did not correlate with blood urea
nitrogen, creatinine, and uric acid levels, ORAIP may
be an independent biomarker of cardiovascular injury
but not renal injury in ESRD patients. Although the
primary mechanism of oxidative stress generation in
ESRD is uncertain, the elevated levels of ORAIP,Kidney International Reports (2016) 1, 321–326
Figure 2. Correlation between plasma levels of oxidative stress-responsive apoptosis inducing protein (ORAIP) and biomarkers for cardiac
injury. (a) Correlation between plasma levels of ORAIP and those of cardiac troponin T (hs-TnT). There was no signiﬁcant correlation (r ¼ 0.0945,
P ¼ 0.4651). (b) Correlation between plasma levels of ORAIP and those of brain natriuretic peptide (BNP). There was no significant correlation
(r ¼ 0.1353, P ¼ 0.2944).
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RESEARCH LETTERSinduced by oxidative stress, may cause renal micro-
vascular injury, resulting in the progression of ESRD.
Our ﬁndings warrant elimination of plasma ORAIP
with a neutralizing antibody against ORAIP2 to pro-
tect against cardiovascular injury and sarcopenia in
dialysis patients.
Kentaro Tanaka1, Takako Yao2,
Tsutomu Fujimura3, Kimie Murayama4,
Shuichi Fukuda5, Ko Okumura6 and
Yoshinori Seko2
1Higashiyamato Nangai Clinic, Tokyo, Japan; 2Division of Cardio-
vascular Medicine, The Institute for Adult Diseases, Asahi Life
Foundation, Tokyo, Japan; 3Laboratory of Bioanalytical Chemistry,
Tohoku Pharmaceutical University, Sendai, Japan; 4Division of
Proteomics and Biomolecular Science, BioMedical Research
Center, Graduate School of Medicine, Juntendo University, Tokyo,
Japan; 5Wakakusa Clinic, Tochigi, Japan; and 6Department of
Atopy Research Center, Juntendo University School of Medicine,
Tokyo, Japan
Corresponding author: E-mail: sekoyosh-tky@umin.ac.jpDISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
This work was supported by Research Fund of Mitsukoshi
Health and Welfare Foundation 2015, and by a grant from
Takeda Research Support.
REFERENCES
1. Locatelli F, Canaud B, Eckardt K-U, et al. Oxidative
stress in end-stage renal disease: an emerging threat
and haemodialysis: role of inﬂammation and duration of
dialysis treatment. Nephrol Dial Transplant. 2001;16:335–340.
9. Jacobs P, Glorieux G, Vanholder R. Interleukin/cytokine pro-
ﬁles in haemodialysis and in continuous peritoneal dialysis.
Nephrol Dial Transplant. 2004;19(suppl 5):V41–V45.
10. Nguyen AT, Lethias C, Zingraff J, et al. Hemodialysis
membrane-induced activation of phagocyte oxidative meta-
bolism detected in vivo and in vitro within microamounts of
whole blood. Kidney Int. 1985;28:158–167.
11. Gondouin B, Jourde-Chiche N, Sallee M, et al. Plasma
xanthine oxidase activity is predictive of cardiovascular dis-
ease in patients with chronic kidney disease, independently
of uric acid levels. Nephron. 2015;131:167–174.
Kidney International Reports (2016) 1, 321–326 323
Received 3 July 2016; revised 5 August 2016; accepted 16
August 2016; published online 23 August 2016
RESEARCH LETTERSª 2016 International Society of Nephrology. Published by
Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
Kidney Int Rep (2016) 1, 321–324; http://dx.doi.org/10.1016/
j.ekir.2016.08.011Needle Size and the Risk
of Kidney Biopsy
Bleeding ComplicationsTo the Editor: The percutaneous renal biopsy is an
essential tool in the diagnosis and evaluation of kidney
disease. Most renal biopsies are performed under direct
ultrasound guidance with automated biopsy needles,
techniques that have substantially reduced the risks of
the procedure.1–3 However, the kidney biopsy still
carries a considerable risk of bleeding complications.
Although certain risk factors for bleeding, including
hypertension, acute kidney injury, female sex, and older
age, have been well documented,4 the association
between the biopsy needle size and the rate of bleeding
complications is unclear. Major complications, including
hemorrhage requiring transfusion, angiographic inter-
vention, nephrectomy, or death, have been reported in
only around 2%–8% of renal biopsies, whereas minor
complications, such as hematoma, are seen in anywhere
from 17% to 33%.4,5 Hematoma formation found on
renal ultrasound is a direct assessment of post-biopsy
bleeding and may be a more sensitive measure of
bleeding than overt anemia or hemodynamic instability.
At our institution, post-biopsy ultrasounds are routinely
obtained as standard of care after kidney biopsy. We
therefore conducted a retrospective cohort study of
patients who underwent kidney biopsy, using post-
biopsy hematoma as the endpoint of interest when
comparing 14G versus 16G needles.
The study was conducted at Brigham and Women’s
Hospital in Boston, MA, between August 2014 and
January 2016. We captured all biopsies that were
performed under the supervision of a single
nephrology attending, allowing for minimal variation
in how procedures in our cohort were supervised and
performed. The biopsies captured comprise the large
majority of the ultrasound-guided renal biopsies con-
ducted during the period of the study.
During the period of the study, the standard of
care switched from the use of 14G to 16G needles,
based on anecdotal observations of excessive numbers324of hematomas noted in the 14G group. Spring-loaded,
automated needles were used for all biopsies. All bi-
opsies were conducted by or under the supervision of
the same nephrology attending, and all patients were
monitored for at least 6 hours after biopsy. A renal
pathologist conﬁrmed the adequacy of the sample at
the time of the biopsy. The presence of a hematoma was
ascertained by immediate post-biopsy ultrasound. We
used electronic health record databases to capture de-
mographic and clinical data. The outcome of interest
was the occurrence of a post-biopsy hematoma. The
secondary outcome was the change in hemoglobin
concentration before and 6 hours after biopsy.
We used a c2 or t-test to compare baseline charac-
teristics between patients with 16G and 14G needles.
We used multivariate logistic regression to test the
association between the needle size and the occurrence
of a post-biopsy hematoma adjusted for clinical and
demographic characteristics. We selected covariates
that were previously shown to be associated with an
increased risk of bleeding after biopsy including age,
sex, needle size, platelet count, systolic blood pressure,
and estimated glomerular ﬁltration rate. We addition-
ally adjusted for fellow performance of biopsies and the
number of passes. Finally, we adjusted for the presence
of >40% ﬁbrosis on the biopsy as this was associated
with a risk of hematoma in the univariate analysis. We
used R, version 3.2.2, for all statistical analyses and
considered P < 0.05 to be statistically signiﬁcant.
Our cohort consisted of 86 patients with a mean age
of 56.5  16.9 years. Baseline characteristics, stratiﬁed
by needle size and by the occurrence of a hematoma,
are shown in Table 1. A 14G biopsy needle was used in
44 (51%) of patients and a 16G biopsy needle was used
in the remaining patients. There were a similar pro-
portion of patients who had inpatient biopsies in the
14G group compared with the 16G group (34% vs.
43%, respectively, P ¼ 0.54). More passes were per-
formed to obtain adequate samples in the 14G group
compared with the 16G group (2.7 vs. 2.2, respectively,
P ¼ 0.003). There was no effect of the number of passes
on the risk of hematoma (P ¼ 0.49).
Hematoma formation was more frequent among in-
dividuals who underwent kidney biopsy using 14G
needles compared with 16G needles (41% vs. 17%,
respectively, P ¼ 0.03). There was no difference in
the diagnostic yield of glomeruli between the 2 groups
(43  21.6 vs. 37  12.3 glomeruli, respectively,
P ¼ 0.13). There were no patients in whom the tissue
obtained was inadequate to make a diagnosis. In a
logistic regression analysis, the use of a 14G needle
was associated with a signiﬁcantly higher risk of he-
matoma (odds ratio 5.72, 95% conﬁdence interval
1.54–25.7, P ¼ 0.01) after multivariable adjustment forKidney International Reports (2016) 1, 321–326
